Short answer
Bausch & Lomb Corp (BLCO) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results announced for quarter ended June 30, 2026.
Bausch & Lomb Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results announced for quarter ended June 30, 2026
- Financial information released through Exhibit 99.1, including quarterly operating performance
- Investor focus: review Exhibit 99.1 for revenue, profitability, guidance and segment trends
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $1.394B, up 9% reported and 8% constant currency, signaling broad-based operating momentum
- Surgical revenue up 19% and Pharmaceuticals up 15%, led by premium IOLs, MIEBO and XIIDRA
- Operating income improved to $83M from an $11M loss, while operating cash flow increased to $153M from $35M
- Adjusted EBITDA excluding acquired IPR&D rose to $246M from $192M, supporting stronger profitability and cash conversion
- 2026 guidance raised: revenue $5.440B-$5.540B and adjusted EBITDA excluding acquired IPR&D $1.025B-$1.075B
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bausch & Lomb Corp 8-K filings
Get the next BLCO 8-K as it lands
Follow BLCO for push alerts, or ask the research agent what this filing means.